Cell therapy (Antigen-specific T cells) · Kills target cells, directed at tumor-associated antigens (TAAs) · developed by Immatics US
IMA101 is a preparation of autologous cytotoxic T-lymphocytes that are isolated from the patient, expanded ex vivo, and reintroduced by intravenous infusion. The cells are selected for their ability to recognize certain tumor-associated antigens, and they target and kill tumor cells. It is studied in cancer and solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02876510 | Phase 1 | Cancer | Completed | IMTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
CancerSolid Tumor
Updated Nov 15, 2026. Something wrong or missing? Report it on the IMTX page.
See IMTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IMTX catalysts and pipeline →